NASDAQ$AMED

Amedisys Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Amedisys reported strong first-quarter results, driven by home health performance and hospice progress despite COVID-19 impacts.

Amedisys reported a revenue increase of $45.4 million, reaching $537.1 million, and net income attributable to Amedisys, Inc. of $49.9 million. The company's Home Health segment showed strong momentum, while the Hospice segment continued to navigate COVID-19 challenges. Amedisys is focused on innovation, inorganic growth, and cash flow generation, positioning itself as a leader in industry consolidation.

  • Net service revenue increased to $537.1 million compared to $491.7 million in 2020.
  • Net income attributable to Amedisys, Inc. reached $49.9 million, up from $31.8 million in 2020.
  • Adjusted net income attributable to Amedisys, Inc. per diluted share was $1.54, compared to $1.05 in 2020.
  • The company updated its 2021 guidance to reflect the extension of the suspension of sequestration through December 31, 2021.

Headline financials

Total Revenue

$537M

Previous: $492M+9.2%
EPS (adj)

$1.54

Previous: $1.05+46.7%
Capital Expenditures

$1.62M

Previous: $1.43M+12.8%
Free Cash Flow

$52.4M

Previous: $4.6M+1038.5%
Net Income

$49.9M

Previous: $31.8M+56.9%
Operating Income

$68.8M

Previous: $43.9M+56.9%
Gross Profit

$240M

Previous: $206M+16.5%
Cash & Equivalents

$77.3M

Previous: $175M-55.7%
Total Assets

$1.57B

Previous: $1.44B+9.2%
Stock-Based Comp

$7.31M

Previous: $5.91M+23.7%

Revenue & EPS history

Amedisys · Revenue · Quarterly

$537M

Q1 2021+9.2%vs Q1 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Forward guidance

Amedisys updated its 2021 revenue guidance to $2.302 billion - $2.342 billion, adjusted EBITDA to $342 million - $352 million, and adjusted diluted EPS to $6.85 - $7.07, reflecting the extension of the suspension of sequestration through December 31, 2021. This excludes any impacts from future acquisitions.

Tailwinds

  • Net service revenue is anticipated to be in the range of $2.302 billion to $2.342 billion.
  • Adjusted EBITDA is anticipated to be in the range of $342 million to $352 million.
  • Adjusted diluted earnings per share is anticipated to be in the range of $6.85 to $7.07.
  • Guidance reflects the extension of the suspension of sequestration through December 31, 2021.
  • The company expects to be at the forefront of industry consolidation.

Headwinds

  • Guidance excludes the effects of any future acquisitions.
  • The home health, hospice and personal care industries are highly competitive.
  • The industries are subject to intensive regulations.
  • Trends are subject to numerous factors, risks, and uncertainties.
  • The COVID-19 pandemic continues to impact business, financial condition and results of operations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports

Historical avg

-0.6%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-5.0%

Avg return

30 days after

46%

32 / 70 earnings

Positive

+25.6%

Q2 2014

Best reaction

-25.3%

Q3 2013

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025
Q2 2025+1.2%+1.0%
Q1 2025+0.2%-0.8%-1.6%
Q4 2024+0.1%+0.6%+1.5%
Q3 2024+0.9%-3.4%-10.4%
Q2 2024+0.0%+0.5%-0.2%
Q1 2024+0.0%+0.8%+5.5%
Q4 2023+0.9%+0.6%-1.6%
Q3 2023-0.8%-1.1%+1.8%
Q2 2023-0.6%-0.2%+2.5%
Q1 2023+4.2%+3.9%+2.8%
Q4 2022+5.4%+2.2%-23.6%
Q3 2022-9.0%-4.2%-10.7%
Q2 2022-3.8%+0.9%-4.5%
Q1 2022+0.4%-3.3%-10.5%
Q4 2021+5.8%+14.5%+18.4%
Q3 2021+0.1%+1.7%-20.2%
Q2 2021-22.8%-22.9%-29.3%
Q1 2021+0.2%
Q4 2020-6.2%
Q3 2020-1.9%
Q2 2020+3.7%
Q1 2020-3.3%
Q4 2019-2.1%
Q3 2019-1.5%
Q2 2019-1.9%
Q1 2019-6.3%
Q4 2018+0.0%
Q3 2018+17.3%
Q2 2018+11.1%
Q1 2018+7.2%
Q4 2017+2.3%
Q3 2017+4.8%
Q2 2017-20.9%
Q1 2017+4.4%
Q4 2016+4.7%
Q3 2016-10.1%
Q2 2016-7.1%
Q1 2016-7.0%
Q4 2015+12.3%
Q3 2015+10.8%
Q2 2015-3.2%
Q1 2015+6.0%
Q4 2014-5.4%
Q3 2014+16.2%
Q2 2014+25.6%
Q1 2014-1.0%
Q4 2013-10.0%
Q3 2013-25.3%
Q2 2013+17.8%
Q1 2013-2.8%
Q4 2012-8.7%
Q3 2012-5.0%
Q2 2012+12.5%
Q1 2012-1.2%
Q4 2011-0.6%
Q3 2011-23.8%
Q2 2011-10.7%
Q1 2011-6.4%
Q4 2010-8.0%
Q3 2010+1.3%
Q2 2010-7.9%
Q1 2009-4.3%
Q1 2010+2.6%
Q4 2007-1.3%
Q4 2009-1.3%
Q3 2008-5.7%
Q3 2009-5.7%
Q4 2008+7.6%
Q2 2008+7.6%
Q2 2009+7.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro